Leite, Jorge

Foto do perfil

Endereço de Email

Data de nascimento

Cargo

Último Nome

Leite

Primeiro Nome

Jorge

Nome

Jorge Leite

Biografia

Jorge Leite obtained his PhD in 2011 from the University of Minho, where he also completed his Psychology Degree in 2005. From 2013 to 2016, he underwent postdoctoral training at the Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School. Currently, he holds the positions of Vice-Rector for Research, Associate Professor, and Coordinator of the CINTESIS.UPT. Throughout his career, he has made significant contributions to the field, with over 70 peer-reviewed publications, including articles in journals, book chapters, and conference proceedings. According to Scopus data, over half of his publications are featured in the top 25% of journals, while 45% are among the top 25% most cited documents globally. He has also supervised numerous MSc dissertations and is currently overseeing four PhD theses. Furthermore, he actively participates in various research projects, taking on roles such as Principal Investigator, Researcher, and Supervisor. These projects have successfully secured over 6M euros in funding. His dedication to his work has been recognized with seven awards and/or honors. Furthermore, he has collaborated with 167 fellow researchers in various scientific endeavors.

Identificadores

0000-0002-0323-9012
A71F-2404-41CE
03piNtgAAAAJ
47761976700
E-4404-2013

Projetos de investigação

Unidades organizacionais

Logótipo da unidade
Organização
CINTESIS.UPT - Centro de Investigação em Tecnologias e Serviços de Saúde
Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS.UPT), former I2P, is an R&D unit devoted to the study of cognition and behaviour in context. With an interdisciplinary focus, namely on Education, Translational and Applied Psychology

Filtros

2022 - 20232
Limpar filtros

Configurações

Autor: Leite, Jorge × Data inicial: 2020 × Assunto: Biomarkers ×

Resultados da pesquisa

A mostrar 1 - 2 de 2
  • Miniatura
    PublicaçãoAcesso Aberto
    Editorial: Optimization strategies for pain management with neuromodulation
    2022-09-15 - Pacheco-Barrios, Kevin; Carvalho, Sandra; Caumo, Wolnei; Fregni, Felipe; Leite, Jorge
    Chronic pain is a high-priority global health issue due to its high prevalence, impact on quality of life, and cost (1). In most cases, chronic pain is challenging to manage, and the existing treatment modalities have reported frequent and severe adverse events, including gastritis (2), cardiovascular complications [...]
  • Miniatura
    PublicaçãoAcesso Restrito
    Non-pharmacological treatment-related changes of molecular biomarkers in major depressive disorder: A systematic review and meta-analysisTagedEnd
    2023-01-24 - Irwin, Courtney L.; Coelho, Patrícia S.; Kluwe-Schiavon, Bruno; Silva-Fernandes, Anabela; Gonçalves, Óscar F.; Carvalho, Sandra; Leite, Jorge
    Background: Major depressive disorder (MDD) is a serious mood disorder and leading cause of disability. Despite treatment advances, approximately 30% of individuals with MDD do not achieve adequate clinical response. Better understanding the biological mechanism(s) underlying clinical response to specific psychopharmacological interventions may help fine tune treatments in order to further modulate their underlying mechanisms of action. However, little is known regarding the effect of non-pharmacological treatments (NPTs) on candidate molecular biomarker levels in MDD. This review aims to identify molecular biomarkers that may elucidate NPT response for MDD. Methods: We performed a systematic review and a multilevel linear mixed-effects meta-analyses, and a metaregression. Searches were performed in PubMed, Scopus, and PsycINFO in October 2020 and July 2021. Results: From 1387 retrieved articles, 17 and six studies were included in the systematic review and meta-analyses, respectively. Although there was little consensus associating molecular biomarker levels with symptomology and/or treatment response, brain metabolites accessed via molecular biomarker-focused neuroimaging techniques may provide promising information on whether an individual with MDD would respond positively to NPTs. Furthermore, non-invasive brain stimulation interventions significantly increased the expression of neurotrophic factors (NTFs) compared to sham/placebo, regardless of add-on pharmacological treatment. Conclusions: NTFs are candidate biomarkers to fine-tune NIBS for MDD treatment.